secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0000950170-23-022872
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint sells YUTIQ to Alimera for $82.5M plus royalties, repays debt, cuts 35 jobs
--------------------------------------------------------------------------------

- Sold YUTIQ rights to Alimera for $75M upfront + $7.5M guaranteed 2024 payments; low-to-mid double-digit royalties on US net sales above thresholds 2025-2028.
- Repaid all $30M outstanding bank debt at closing, including prepayment and exit fees.
- Executing workforce reduction of ~35 employees (sales/marketing and support); expects $1.2-1.6M pre-tax charges in Q2-Q3 2023.
- Extends cash runway into 2025, beyond key EYP-1901 Phase 2 trial readouts.
- Company transforms to pure-play drug developer focusing on EYP-1901 sustained delivery treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023022872/0000950170-23-022872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017023022872/eypt-20230517.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-022872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer